3 Resilient Dividend Stocks to Consider During a Stock Market Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2025
0mins
Source: NASDAQ.COM
AbbVie and Its Resilience: AbbVie is highlighted as a strong investment due to its robust pipeline and consistent dividend payments, making it likely to withstand market downturns better than many other stocks.
Enterprise Products Partners' Stability: This midstream energy company is noted for its reliable cash flow and long-term contracts, making it a solid choice for dividend investors, especially with a distribution yield of 6.8%.
Pfizer's Attractive Dividend: Despite facing challenges like a patent cliff, Pfizer offers a high dividend yield of 7.15% and has a promising pipeline of products that could mitigate potential sales declines.
Market Outlook and Investment Strategy: The article warns of potential market corrections due to high valuations and suggests considering the top 10 stocks identified by analysts for better investment opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 212.930
Low
223.00
Averages
252.00
High
289.00
Current: 212.930
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AQUIPTA® Approved in EU for Migraine Treatment
- Clinical Trial Success: AQUIPTA® demonstrated significant efficacy in the Phase 3 ECLIPSE trial, achieving pain freedom within two hours after the first migraine attack and maintaining effects from 2 to 48 hours, indicating its effectiveness and reliability in acute treatment.
- Market Expansion: This approval makes AQUIPTA® the second drug in the EU to receive indications for both acute and preventive migraine treatment, further enriching AbbVie's portfolio in the migraine therapy space and addressing diverse patient needs.
- Economic Burden Reduction: Migraine contributes an estimated 1.2% to 2.0% of GDP in economic losses in Europe, equating to €35 billion to €557 billion in productivity losses, and the approval of AQUIPTA® is expected to alleviate this burden by providing effective treatment options.
- Improved Patient Quality of Life: The rapid and sustained relief provided by AQUIPTA® will help patients better manage their migraines, enhancing their quality of life and reducing the impact of migraines on daily activities, reflecting AbbVie's commitment to addressing patient needs.
See More
AbbVie's Strong Earnings and Skyrizi's Promising Outlook Amid Competition
- Strong Financial Performance: AbbVie's first-quarter earnings exceeded expectations, showcasing robust revenue and profit growth, which indicates the company's strong profitability in a competitive market and is likely to continue attracting investor interest.
- Skyrizi's Market Position Secure: Despite Johnson & Johnson's launch of Icotyde as a competitor, Skyrizi demonstrated a significant efficacy with approximately 70% of patients achieving PASI 90 in clinical trials, far surpassing Icotyde's 50%, thereby solidifying Skyrizi's leadership in psoriasis treatment.
- Sales Forecast Upgrade: AbbVie raised its 2027 sales forecast for Skyrizi and Rinvoq from $27 billion to $31 billion, reflecting strong market demand and confidence in the future growth potential of these two immunosuppressants.
- Consistent Dividend Growth: AbbVie offers a 3.2% dividend yield and has increased its payouts for 54 consecutive years, earning the title of 'Dividend King', which not only boosts investor confidence but also provides a foundation for the company's future financial stability.
See More
USCL Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: USCL's 52-week low is $70.34 per share, with a high of $85.57, and the latest trade at $85.42 indicates the stock is fluctuating near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and identify potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in outstanding shares for ETFs helps identify those experiencing significant inflows or outflows, allowing investors to evaluate the impact on underlying assets and make more informed investment decisions.
See More
S&P 500 Resilience Sparks Interest in High Dividend Stocks
- AbbVie Investment Value: AbbVie has a market cap of approximately $375 billion, and while its P/E ratio exceeds 100, its forward P/E is only 15, significantly below the S&P 500 average of 22, indicating the stock is undervalued and suitable for long-term investment.
- Strong Cash Flow: AbbVie generated nearly $20 billion in free cash flow over the past 12 months, sufficient to support its 3.3% dividend, with $11.8 billion paid in dividends over the last four quarters, demonstrating financial health.
- CVS Health Recovery: CVS Health's stock has risen 14% this year, with free cash flow totaling $7.4 billion, far exceeding the $3.4 billion in dividends paid, indicating robust operations and promising growth potential.
- Verizon's High Dividend Appeal: Verizon offers a dividend yield of 5.9%, and despite a 17% stock price increase, its free cash flow of nearly $20 billion comfortably covers its $11.5 billion in annual dividends, showcasing dividend safety and growth potential.
See More
European Commission Approves AbbVie's Aquipta for Migraine Treatment
- New Drug Approval: The European Commission has approved AbbVie's Aquipta (atogepant) for migraine treatment, based on results from the ECLIPSE phase 3 trial that demonstrated statistically significant pain freedom at two hours compared to placebo, which is expected to enhance AbbVie's penetration in the migraine market.
- Clinical Trial Results: The ECLIPSE trial results indicate that atogepant offers an effective new treatment option, particularly for patients who have not benefited from traditional therapies, potentially significantly boosting AbbVie's competitive position in the market.
- Drug Mechanism: Atogepant is an oral calcitonin gene-related peptide receptor antagonist already approved for migraine prophylaxis, and the new indication will further expand its market application, enhancing AbbVie's product portfolio.
- Market Outlook: With the approval of Aquipta, AbbVie's market potential in migraine treatment is set to increase significantly, likely leading to substantial revenue growth for the company while providing patients with more treatment options, aligning with the current healthcare market's demand for innovative therapies.
See More
AbbVie’s AQUIPTA Approved by EU for Acute Migraine Treatment
- EU Approval for New Indication: AbbVie announced that its oral medication AQUIPTA (atogepant) has received approval from the European Commission for the acute treatment of migraine, marking the second indication for the drug in the EU and addressing urgent treatment needs.
- Clinical Data Support: The ECLIPSE study demonstrated that AQUIPTA significantly outperformed placebo in achieving pain freedom within two hours post-treatment (p<0.0001), providing strong clinical evidence for healthcare providers.
- Economic Burden Analysis: Migraine contributes an estimated economic burden of 1.2% to 2.0% of GDP in six European countries, translating to €35 billion to €557 billion in lost productivity, highlighting the significant impact of this condition on society and healthcare systems.
- Improvement in Patient Quality of Life: The approval of AQUIPTA not only offers acute and preventive treatment options for migraine patients but also has the potential to enhance their quality of life by alleviating psychological and social burdens, thereby strengthening AbbVie's market position in the neuroscience sector.
See More
AQUIPTA® Approved in EU for Migraine Treatment
- Clinical Trial Success: AQUIPTA® demonstrated significant efficacy in the Phase 3 ECLIPSE trial, achieving pain freedom within two hours after the first migraine attack and maintaining effects from 2 to 48 hours, indicating its effectiveness and reliability in acute treatment.
- Market Expansion: This approval makes AQUIPTA® the second drug in the EU to receive indications for both acute and preventive migraine treatment, further enriching AbbVie's portfolio in the migraine therapy space and addressing diverse patient needs.
- Economic Burden Reduction: Migraine contributes an estimated 1.2% to 2.0% of GDP in economic losses in Europe, equating to €35 billion to €557 billion in productivity losses, and the approval of AQUIPTA® is expected to alleviate this burden by providing effective treatment options.
- Improved Patient Quality of Life: The rapid and sustained relief provided by AQUIPTA® will help patients better manage their migraines, enhancing their quality of life and reducing the impact of migraines on daily activities, reflecting AbbVie's commitment to addressing patient needs.
See More
AbbVie's Strong Earnings and Skyrizi's Promising Outlook Amid Competition
- Strong Financial Performance: AbbVie's first-quarter earnings exceeded expectations, showcasing robust revenue and profit growth, which indicates the company's strong profitability in a competitive market and is likely to continue attracting investor interest.
- Skyrizi's Market Position Secure: Despite Johnson & Johnson's launch of Icotyde as a competitor, Skyrizi demonstrated a significant efficacy with approximately 70% of patients achieving PASI 90 in clinical trials, far surpassing Icotyde's 50%, thereby solidifying Skyrizi's leadership in psoriasis treatment.
- Sales Forecast Upgrade: AbbVie raised its 2027 sales forecast for Skyrizi and Rinvoq from $27 billion to $31 billion, reflecting strong market demand and confidence in the future growth potential of these two immunosuppressants.
- Consistent Dividend Growth: AbbVie offers a 3.2% dividend yield and has increased its payouts for 54 consecutive years, earning the title of 'Dividend King', which not only boosts investor confidence but also provides a foundation for the company's future financial stability.
See More
USCL Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: USCL's 52-week low is $70.34 per share, with a high of $85.57, and the latest trade at $85.42 indicates the stock is fluctuating near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and identify potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in outstanding shares for ETFs helps identify those experiencing significant inflows or outflows, allowing investors to evaluate the impact on underlying assets and make more informed investment decisions.
See More
S&P 500 Resilience Sparks Interest in High Dividend Stocks
- AbbVie Investment Value: AbbVie has a market cap of approximately $375 billion, and while its P/E ratio exceeds 100, its forward P/E is only 15, significantly below the S&P 500 average of 22, indicating the stock is undervalued and suitable for long-term investment.
- Strong Cash Flow: AbbVie generated nearly $20 billion in free cash flow over the past 12 months, sufficient to support its 3.3% dividend, with $11.8 billion paid in dividends over the last four quarters, demonstrating financial health.
- CVS Health Recovery: CVS Health's stock has risen 14% this year, with free cash flow totaling $7.4 billion, far exceeding the $3.4 billion in dividends paid, indicating robust operations and promising growth potential.
- Verizon's High Dividend Appeal: Verizon offers a dividend yield of 5.9%, and despite a 17% stock price increase, its free cash flow of nearly $20 billion comfortably covers its $11.5 billion in annual dividends, showcasing dividend safety and growth potential.
See More
European Commission Approves AbbVie's Aquipta for Migraine Treatment
- New Drug Approval: The European Commission has approved AbbVie's Aquipta (atogepant) for migraine treatment, based on results from the ECLIPSE phase 3 trial that demonstrated statistically significant pain freedom at two hours compared to placebo, which is expected to enhance AbbVie's penetration in the migraine market.
- Clinical Trial Results: The ECLIPSE trial results indicate that atogepant offers an effective new treatment option, particularly for patients who have not benefited from traditional therapies, potentially significantly boosting AbbVie's competitive position in the market.
- Drug Mechanism: Atogepant is an oral calcitonin gene-related peptide receptor antagonist already approved for migraine prophylaxis, and the new indication will further expand its market application, enhancing AbbVie's product portfolio.
- Market Outlook: With the approval of Aquipta, AbbVie's market potential in migraine treatment is set to increase significantly, likely leading to substantial revenue growth for the company while providing patients with more treatment options, aligning with the current healthcare market's demand for innovative therapies.
See More
AbbVie’s AQUIPTA Approved by EU for Acute Migraine Treatment
- EU Approval for New Indication: AbbVie announced that its oral medication AQUIPTA (atogepant) has received approval from the European Commission for the acute treatment of migraine, marking the second indication for the drug in the EU and addressing urgent treatment needs.
- Clinical Data Support: The ECLIPSE study demonstrated that AQUIPTA significantly outperformed placebo in achieving pain freedom within two hours post-treatment (p<0.0001), providing strong clinical evidence for healthcare providers.
- Economic Burden Analysis: Migraine contributes an estimated economic burden of 1.2% to 2.0% of GDP in six European countries, translating to €35 billion to €557 billion in lost productivity, highlighting the significant impact of this condition on society and healthcare systems.
- Improvement in Patient Quality of Life: The approval of AQUIPTA not only offers acute and preventive treatment options for migraine patients but also has the potential to enhance their quality of life by alleviating psychological and social burdens, thereby strengthening AbbVie's market position in the neuroscience sector.
See More
